These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12744866)

  • 21. Recurrence risk of oculorespiratory syndrome after influenza vaccination: randomized controlled trial of previously affected persons.
    De Serres G; Skowronski DM; Guay M; Rochette L; Jacobsen K; Fuller T; Duval B
    Arch Intern Med; 2004 Nov; 164(20):2266-72. PubMed ID: 15534165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oculo-respiratory syndrome in association with the influenza vaccine: Canada, October-November 2000.
    Can Commun Dis Rep; 2000 Dec; 26(23):201-2. PubMed ID: 11149349
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada.
    Rouleau I; De Serres G; Skowronski DM; Drolet JP; Lemire C; Toth E; Landry M
    Vaccine; 2014 Jun; 32(28):3480-7. PubMed ID: 24793951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seasonal influenza vaccines.
    Fiore AE; Bridges CB; Cox NJ
    Curr Top Microbiol Immunol; 2009; 333():43-82. PubMed ID: 19768400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model.
    Babiuk S; Skowronski DM; De Serres G; HayGlass K; Brunham RC; Babiuk L
    J Med Virol; 2004 Jan; 72(1):138-42. PubMed ID: 14635022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse ocular effects following influenza vaccination.
    Solomon A; Siganos CS; Frucht-Pery J
    Eye (Lond); 1999 Jun; 13 ( Pt 3a)():381-2. PubMed ID: 10624444
    [No Abstract]   [Full Text] [Related]  

  • 27. Influenza a common viral infection among Hajj pilgrims: time for routine surveillance and vaccination.
    Balkhy HH; Memish ZA; Bafaqeer S; Almuneef MA
    J Travel Med; 2004; 11(2):82-6. PubMed ID: 15109471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children.
    Piedra PA; Yan L; Kotloff K; Zangwill K; Bernstein DI; King J; Treanor J; Munoz F; Wolff M; Cho I; Mendelman PM; Cordova J; Belshe RB
    Pediatrics; 2002 Oct; 110(4):662-72. PubMed ID: 12359778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010.
    Polakowski LL; Sandhu SK; Martin DB; Ball R; Macurdy TE; Franks RL; Gibbs JM; Kropp GF; Avagyan A; Kelman JA; Worrall CM; Sun G; Kliman RE; Burwen DR
    Am J Epidemiol; 2013 Sep; 178(6):962-73. PubMed ID: 23652165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM; Aoki F; Ward BJ; McGeer A; Angel JB; Stiver G; Gorfinkel I; Shu D; White L; Lasko B; Dzongowski P; Papp K; Alexander M; Boivin G; Fries L
    Vaccine; 2011 Feb; 29(10):1921-8. PubMed ID: 21219987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse effects associated with influenza vaccination in patients with COPD: a randomized controlled study.
    Wongsurakiat P; Maranetra KN; Gulprasutdilog P; Aksornint M; Srilum W; Ruengjam C; Sated W
    Respirology; 2004 Nov; 9(4):550-6. PubMed ID: 15612969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse reactions to equine vaccinations: a preliminary survey.
    Mair TS
    Vet Rec; 1988 Apr; 122(16):396. PubMed ID: 3394223
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety of live-attenuated influenza vaccination in cystic fibrosis.
    Boikos C; De Serres G; Lands LC; Boucher FD; Tapiéro B; Daigneault P; Quach C
    Pediatrics; 2014 Oct; 134(4):e983-91. PubMed ID: 25225145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guillain-Barré syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition.
    Choe YJ; Cho H; Bae GR; Lee JK
    Vaccine; 2011 Mar; 29(11):2066-70. PubMed ID: 21255684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean.
    Ropero-Álvarez AM; Whittembury A; Bravo-Alcántara P; Kurtis HJ; Danovaro-Holliday MC; Velandia-González M
    Vaccine; 2015 Jan; 33(1):187-92. PubMed ID: 25444798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Woo EJ; Moro PL; Cano M; Jankosky C
    Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse events following immunization (AEFI) with the novel influenza a (H1N1) 2009 vaccine: findings from the national registry of all vaccine recipients and AEFI and the passive surveillance system in South Korea.
    Kim JH; Cho HY; Hennessey KA; Lee HJ; Bae GR; Kim HC
    Jpn J Infect Dis; 2012; 65(2):99-104. PubMed ID: 22446114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection.
    Masurel N; Laufer J
    J Hyg (Lond); 1984 Jun; 92(3):263-76. PubMed ID: 6736638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of influenza vaccination for children in Japan: Four-year observational study using a large-scale claims database.
    Shibata N; Kimura S; Hoshino T; Takeuchi M; Urushihara H
    Vaccine; 2018 May; 36(20):2809-2815. PubMed ID: 29661585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of vaccination on influenza mortality in children <5years old in Mexico.
    Sánchez-Ramos EL; Monárrez-Espino J; Noyola DE
    Vaccine; 2017 Mar; 35(9):1287-1292. PubMed ID: 28162824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.